Company Overview of Deciphera Pharmaceuticals, LLC
Deciphera Pharmaceuticals, LLC engages in the design, development, and commercialization of kinase-inhibiting drugs for the treatment of cancers and immunological diseases. The company develops therapeutic agents against leukemia, invasive cancers, melanoma, gastrointestinal stromal tumors, bone metastases, and autoimmune diseases. Its drug pipeline comprises DCC-2036 for chronic myeloid leukemia, acute lymphocytic leukemia, and acute myeloid leukemia; DCC-2618 for gastrointestinal stromal tumors, mast cell leukemia, and mastocytosis; DCC-2701 and DCC-2721 for solid tumors and metastatic cancers; DCC-2909 for cancer invasiveness and bone metastasis; and cFMS kinase program for autoimmune dis...
Lawrence, KS 66044
Founded in 2003
Key Executives for Deciphera Pharmaceuticals, LLC
Chief Executive Officer, President and Member of the Board of Managers
Founder, Chief Scientific Officer and Member of the Board of Managers
Head of Regulatory Affairs & Clinical Operations
Compensation as of Fiscal Year 2014.
Deciphera Pharmaceuticals, LLC Key Developments
Deciphera Pharmaceuticals Appoints Oliver Rosen as Chief Medical Officer
Jun 30 14
Deciphera Pharmaceuticals announced the appointment of Oliver Rosen, M.D., as Chief Medical Officer. Dr. Rosen will be responsible for leading the company's clinical development strategy and clinical operations which includes a pipeline of cancer therapeutics targeting kinases that play an important role in tumor communication with the surrounding tissue. Prior to joining Deciphera, Dr. Rosen held clinical positions in the oncology field at premier biopharmaceutical companies, including Millennium, Genentech, Amgen, Hoffman La Roche and Merck KGaA.
Deciphera Pharmaceuticals Announces Initiation of Phase 1 Cancer Trial for Altiratinib (DCC-2701) MET/TIE2/VEGFR2/TRK Kinase Inhibitor for Solid Tumors
May 30 14
Deciphera Pharmaceuticals announced the initiation of a Phase 1 clinical trial of its MET/TIE2/VEGFR2/TRK inhibitor altiratinib (DCC-2701). The Phase 1 trial will evaluate the safety, tolerability and initial efficacy of altiratinib in cancer patients with solid tumors. Altiratinib has been shown to exhibit high potency and selectivity for inhibiting MET, TIE2, VEGFR2, and TRK kinases in preclinical studies. A companion diagnostic assay will also be co-developed during the course of clinical studies. In preclinical cancer models, altiratinib has shown impressive activity against multiple tumors including melanoma, ovarian, glioblastoma, colorectal, gastric and breast cancers. Altiratinib is an oral, small molecule shown to exhibit high potency and selectivity for inhibiting MET, TIE2, VEGFR2 and TRK kinases in cellular and in vivo cancer studies. Inhibition of MET kinase blocks a key mechanism in tumor cells that causes cancer invasiveness and metastasis. Altiratinib also inhibits activation loop oncogenic MET mutants known to drive certain cancers including papillary renal cell carcinoma. Inhibition of these key kinases also blocks major mechanisms of tumor microenvironment invasiveness and metastasis. By inhibiting these kinases altiratinib blocks the mechanisms that tumors use to build new blood vessels required for tumor growth offering the potential to more durably inhibit tumor blood vessel formation than approaches that only impact one of these pathways. In addition, inhibition of TRK signaling has been shown to be an important mechanism for treatment of a wide range of tumors.
Deciphera Pharmaceuticals Announces Executive and Management Changes; to Open New Corporate Offices in the Boston Area
Apr 7 14
Deciphera Pharmaceuticals announced that it has appointed Michael D. Taylor, Ph.D., as the company's President and Chief Executive Officer. Dr. Taylor takes on the role of CEO at a time when Deciphera is making clinical progress with its kinase inhibitor product candidates for several types of cancers. He is a seasoned biopharmaceutical leader with experience from drug discovery through clinical development and product commercialization. Dr. Taylor has also been appointed to the Board of Managers for Deciphera. Daniel L. Flynn, Ph.D., who is the Founder of Deciphera and previously served as President and Chief Executive Officer, will take the role as Chief Scientific Officer and continue to be a member of the company's Board of Managers. Prior to joining Deciphera, Michael D. Taylor, Ph.D. was CEO of Ensemble Therapeutics where he completed research alliances with Roche, Bristol-Myers Squibb, Pfizer, Genentech, Boehringer Ingelheim, Alexion, and Novartis.
Additionally, as part of the company's evolution, Deciphera will open new corporate offices in the Boston area. The company's current research facilities will remain in Lawrence, Kansas, in close proximity to the University of Kansas.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|